IL-13

Home
Ligands
IL-13 (Human)

GtoPdb Ligand ID: 4980

Synonyms: hematopoietic growth factor | interleukin-13 | mast cell growth factor | multipotential colony-stimulating factor | P-cell-stimulating factor

Compound class: Endogenous peptide in human, mouse or rat

Comment: IL-13 shares sequence and structural homology with IL-4.

Species: Human

References
1. Adams B. Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease. Accessed on 09/02/2018. Modified on 09/02/2018. fiercebiotech.com, https://www.fiercebiotech.com/biotech/sanofi-ditches-il4-il13-antibody-drug-lung-scarring-disease
2. Campbell EM, Parveen S, Buechler J, Valkirs G. (2015) Methods of using anti-IL13 human antibodies. Patent number: US8992916 B2. Assignee: Novartis Ag.. Priority date: 21/10/2005. Publication date: 31/03/2015.
3. Gozzard N, Lawson ADG,LIghtwood DJ, Palframan RT, Smith BJ, Tyson KL. (2014) Antibody molecules having binding specificity for human IL-13. Patent number: US8691233. Assignee: Ucb Pharma S.A.. Priority date: 11/03/2009. Publication date: 08/04/2014.
4. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WO et al.. (2010) A large-scale, consortium-based genomewide association study of asthma. N Engl J Med, 363 (13): 1211-21. [PMID:20860503]
5. Paternoster L, Standl M, Chen CM, Ramasamy A, Bønnelykke K, Duijts L, Ferreira MA, Alves AC, Thyssen JP, Albrecht E et al.. (2012) Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis. Nat Genet, 44 (2): 187-92. [PMID:22197932]
6. Thom G, Minter R. (2012) Optimization of CAT-354, a therapeutic antibody directed against interleukin-13, using ribosome display. Methods Mol Biol, 805: 393-401. [PMID:22094818]
7. Wynn TA. (2003) IL-13 effector functions. Annu Rev Immunol, 21: 425-56. [PMID:12615888]

References

1. Adams B.
Sanofi ditches IL-4/IL-13 antibody drug in lung-scarring disease.
Accessed on 09/02/2018. Modified on 09/02/2018. fiercebiotech.com, https://www.fiercebiotech.com/biotech/sanofi-ditches-il4-il13-antibody-drug-lung-scarring-disease

2. Campbell EM, Parveen S, Buechler J, Valkirs G. (2015)
Methods of using anti-IL13 human antibodies.
Patent number: US8992916 B2. Assignee: Novartis Ag.. Priority date: 21/10/2005. Publication date: 31/03/2015.

3. Gozzard N, Lawson ADG,LIghtwood DJ, Palframan RT, Smith BJ, Tyson KL. (2014)
Antibody molecules having binding specificity for human IL-13.
Patent number: US8691233. Assignee: Ucb Pharma S.A.. Priority date: 11/03/2009. Publication date: 08/04/2014.

4. Moffatt MF, Gut IG, Demenais F, Strachan DP, Bouzigon E, Heath S, von Mutius E, Farrall M, Lathrop M, Cookson WO et al.. (2010)
A large-scale, consortium-based genomewide association study of asthma.
N Engl J Med, 363 (13): 1211-21. [PMID:20860503]

5. Paternoster L, Standl M, Chen CM, Ramasamy A, Bønnelykke K, Duijts L, Ferreira MA, Alves AC, Thyssen JP, Albrecht E et al.. (2012)
Meta-analysis of genome-wide association studies identifies three new risk loci for atopic dermatitis.
Nat Genet, 44 (2): 187-92. [PMID:22197932]

6. Thom G, Minter R. (2012)
Optimization of CAT-354, a therapeutic antibody directed against interleukin-13, using ribosome display.
Methods Mol Biol, 805: 393-401. [PMID:22094818]

7. Wynn TA. (2003)
IL-13 effector functions.
Annu Rev Immunol, 21: 425-56. [PMID:12615888]